X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will advance the development of Q32 Bio’s two clinical development candidates, ADX-914 (bempikibart) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders.
Lead Product(s): Bempikibart
Therapeutic Area: Dermatology Product Name: ADX-914
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Homology Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 25, 2024
Details:
The proceeds will be used to advance the clinical development of Q32 Bio’s two wholly owned assets, ADX-914 (bempikibart), in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders.
Lead Product(s): Bempikibart
Therapeutic Area: Dermatology Product Name: ADX-914
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $42.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 25, 2024
Details:
The combined company will advance the development of Q32 Bio’s two clinical development candidates, ADX-914 (bempikibart) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders.
Lead Product(s): Bempikibart
Therapeutic Area: Dermatology Product Name: ADX-914
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Homology Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 16, 2023
Details:
The proceeds will be used to advance the clinical development of Q32 Bio’s two wholly owned assets, ADX-914 (bempikibart), in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders.
Lead Product(s): Bempikibart
Therapeutic Area: Dermatology Product Name: ADX-914
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $42.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 16, 2023
Details:
ADX-914 (bempikibart) is a fully human anti-IL-7R alpha antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, which is investigated for the treatment of severe alopecia areata.
Lead Product(s): Bempikibart
Therapeutic Area: Dermatology Product Name: ADX-914
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Horizon Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP in patients suffering from moderate to severe atopic dermatitis.
Lead Product(s): ADX-914
Therapeutic Area: Dermatology Product Name: ADX-914
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Horizon Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Under the terms of the agreement, Horizon will fund development through completion of the two Phase 2 trials of ADX-914, with Q32 being operationally responsible for the conduct of all program-related activities.
Lead Product(s): ADX-914
Therapeutic Area: Immunology Product Name: ADX-914
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Horizon Therapeutics
Deal Size: $700.0 million Upfront Cash: $55.0 million
Deal Type: Collaboration August 15, 2022
Details:
Data for ADX-097, a bi-functional fusion protein comprising a humanized anti-C3d monoclonal antibody showed that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition.
Lead Product(s): ADX-097
Therapeutic Area: Nephrology Product Name: ADX-097
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
In preclinical studies, ADX-097 demonstrated the potential to potently inhibit disease-causing complement activation in the tissue while avoiding systemic complement inhibition.
Lead Product(s): ADX-097
Therapeutic Area: Dermatology Product Name: ADX-097
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
ADX-097, a humanized anti-C3d monoclonal antibody next generation complement inhibitor binds to high-density glomerular C3d across a range of renal disease models.
Lead Product(s): ADX-097
Therapeutic Area: Nephrology Product Name: ADX-097
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
